RT @runthelistpod: REFs (3/3) [16,17]https://t.co/FnjJrTYg3S [18]https://t.co/dVsf0ZI0PJ [18]https://t.co/WbAfWiwxTT
REFs (3/3) [16,17]https://t.co/FnjJrTYg3S [18]https://t.co/dVsf0ZI0PJ [18]https://t.co/WbAfWiwxTT
RT @BSCCardiology: JACC: Final analysis of CAP/CAP2 registry data confirms the long-term safety, efficacy of WATCHMAN™ #LAAC device, includ…
JACC: Final analysis of CAP/CAP2 registry data confirms the long-term safety, efficacy of WATCHMAN™ #LAAC device, including significant relative ischemic #stroke reductions compared with expected rates. https://t.co/LRWScRKeGV Safety Info: https://t.co/w
RT @BSCCardiology: JACC: Final analysis of CAP/CAP2 registry data confirms the long-term safety, efficacy of WATCHMAN™ #LAAC device, includ…
RT @BSCCardiology: JACC: Final analysis of CAP/CAP2 registry data confirms the long-term safety, efficacy of WATCHMAN™ #LAAC device, includ…
JACC: Final analysis of CAP/CAP2 registry data confirms the long-term safety, efficacy of WATCHMAN™ #LAAC device, including significant relative ischemic #stroke reductions compared with expected rates. https://t.co/oneGPXmkV1 Safety Info: https://t.co/0
RT @BSCCardiology: JACC: Final analysis of CAP/CAP2 registry data confirms the long-term safety, efficacy of WATCHMAN™ #LAAC device, includ…
RT @BSCCardiology: JACC: Final analysis of CAP/CAP2 registry data confirms the long-term safety, efficacy of WATCHMAN™ #LAAC device, includ…
RT @BSCCardiology: JACC: Final analysis of CAP/CAP2 registry data confirms the long-term safety, efficacy of WATCHMAN™ #LAAC device, includ…
JACC: Final analysis of CAP/CAP2 registry data confirms the long-term safety, efficacy of WATCHMAN™ #LAAC device, including significant relative ischemic #stroke reductions compared with expected rates. https://t.co/MRvZMZVqG0 Safety Info: https://t.co/5
RT @BSCCardiology: Final analysis of CAP/CAP2 registry data confirms long-term safety & efficacy of WATCHMAN™ device, including 69-78% rela…
Final analysis of CAP/CAP2 registry data confirms long-term safety & efficacy of WATCHMAN™ device, including 69-78% relative risk reductions in ischemic stroke compared to expected rates based on CHA2DS2-VASc score. https://t.co/OetWlPTfZl Safety Info
#JACC: Latest registry analysis represents largest number and longest follow-up of trial patients implanted with the WATCHMAN™ #LAAC device. https://t.co/OetWlPTfZl via @JACCJournals https://t.co/ov2TL3DRBr
RT @BSCCardiology: JACC: Final analysis of CAP/CAP2 registry data confirms the long-term safety, efficacy of WATCHMAN™ #LAAC device, includ…
JACC: Final analysis of CAP/CAP2 registry data confirms the long-term safety, efficacy of WATCHMAN™ #LAAC device, including significant relative ischemic #stroke reductions compared with expected rates. https://t.co/K6yZWVwEJv Safety Info: https://t.co/6
Seems like a consistent rate of LAAO DRT emerging - 2.5-4%... why no association w/ stroke? Too soon to tell? 🤔 @TJaredBunch @JonPicciniSr @drjohnm https://t.co/ScFHdTQ465 https://t.co/mu4uv2pvsl
RT @BSCCardiology: Final analysis of CAP/CAP2 registry data confirms long-term safety & efficacy of WATCHMAN™ device, including 69-78% rela…
RT @BSCCardiology: #JACC: New registry analysis represents largest number and longest follow-up of trial patients implanted with the WATCHM…
#JACC: New registry analysis represents largest number and longest follow-up of trial patients implanted with the WATCHMAN™ #LAAC device. via @JACCJournals https://t.co/OetWlQaRnV Safety Info: https://t.co/0nXH59XSkk https://t.co/Uw4UuduKuj
RT @BSCCardiology: Final analysis of CAP/CAP2 registry data confirms long-term safety & efficacy of WATCHMAN™ device, including 69-78% rela…
RT @BSCCardiology: Final analysis of CAP/CAP2 registry data confirms long-term safety & efficacy of WATCHMAN™ device, including 69-78% rela…
RT @BSCCardiology: Final analysis of CAP/CAP2 registry data confirms long-term safety & efficacy of WATCHMAN™ device, including 69-78% rela…
RT @BSCCardiology: Final analysis of CAP/CAP2 registry data confirms long-term safety & efficacy of WATCHMAN™ device, including 69-78% rela…
RT @BSCCardiology: Final analysis of CAP/CAP2 registry data confirms long-term safety & efficacy of WATCHMAN™ device, including 69-78% rela…
RT @BSCCardiology: Final analysis of CAP/CAP2 registry data confirms long-term safety & efficacy of WATCHMAN™ device, including 69-78% rela…
Final analysis of CAP/CAP2 registry data confirms long-term safety & efficacy of WATCHMAN™ device, including 69-78% relative risk reductions in ischemic stroke compared to expected rates based on CHA2DS2-VASc score. https://t.co/D4lTvJVKPz Safety Inf
The longest and largest follow-up data of patients with the Watchman device, support LAAC as a safe and effective therapy for long-term anticoagulation in patients with nonvalvular #AFib #EPeeps https://t.co/dQhuvcfBKH
RT @JACCJournals: Are you regularly using #cvLAAoccluder devices for your patients who cannot tolerate long-term #cvCoag? New #JACC study s…
RT @JACCJournals: Are you regularly using #cvLAAoccluder devices for your patients who cannot tolerate long-term #cvCoag? New #JACC study s…
RT @JACCJournals: Are you regularly using #cvLAAoccluder devices for your patients who cannot tolerate long-term #cvCoag? New #JACC study s…
Are you regularly using #cvLAAoccluder devices for your patients who cannot tolerate long-term #cvCoag? New #JACC study suggests they’re quite safe and effective. What do you think? https://t.co/YStPjbcOgP https://t.co/ebvZw49YJH
RT @JACCJournals: New #JACC study reports on the long-term outcomes of #cvLAAoccluder devices for #stroke prevention in patients with nonva…
RT @JACCJournals: New #JACC study reports on the long-term outcomes of #cvLAAoccluder devices for #stroke prevention in patients with nonva…
RT @JACCJournals: New #JACC study reports on the long-term outcomes of #cvLAAoccluder devices for #stroke prevention in patients with nonva…
RT @JACCJournals: New #JACC study reports on the long-term outcomes of #cvLAAoccluder devices for #stroke prevention in patients with nonva…
RT @JACCJournals: New #JACC study reports on the long-term outcomes of #cvLAAoccluder devices for #stroke prevention in patients with nonva…
RT @JACCJournals: New #JACC study reports on the long-term outcomes of #cvLAAoccluder devices for #stroke prevention in patients with nonva…
New #JACC study reports on the long-term outcomes of #cvLAAoccluder devices for #stroke prevention in patients with nonvalvular #AFib using data from two @FDADeviceInfo mandated registries. https://t.co/YStPjbcOgP https://t.co/SZ6yzKZdo8